Brian Scanlan, chief business officer of Cambridge Major Laboratories, said: “Chemistry Playbook accelerates drug development from carbon to commercialization by delivering where other competitive, expedited programs fall short: program execution.”
Derek Hennecke, CEO and president of Xcelience, said: “Fixed timelines and price are easy to guarantee under ideal conditions (simple API synthesis, straightforward physical properties, or easy-to-formulate products), but in reality these are rare cases.”
“Recognizing that each drug development candidate is unique, we fit the process to the situation, not the other way around,” Xcelience said.
The company said that quality can vary across functional business units within larger service providers, but Chemistry Playbook’s consortium model guarantees functional expertise and accountability at every stage.
Chemistry Playbook has been launched by the consortium on March 4 at a symposium at the headquarters of the Massachusetts Medical Society in Waltham, MA.